Investigating new immunotherapy options for osteosarcoma
Exploration of different immunotherapy modalities in osteosarcoma
This study is looking at new ways to help the immune system fight osteosarcoma, a type of bone cancer, by using special treatments like CAR T cells and oncolytic viruses, with the goal of making things better for patients dealing with this condition.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auburn University at Auburn NIH-funded |
| Lab location | 1 site (Auburn, UNITED STATES) |
| Project ID | NIH-10730833 on NIH RePORTER |
What this research studies
This research explores innovative immunotherapy approaches for treating osteosarcoma, a common bone cancer in both children and adults. The study focuses on using chimeric antigen receptor (CAR) T cells and immune checkpoint inhibitors, such as monoclonal antibodies, to enhance the immune response against tumor cells. Additionally, it examines the use of oncolytic viruses that can specifically target tumor cells and stimulate the immune system within the tumor microenvironment. By combining these strategies, the research aims to improve treatment outcomes for patients with osteosarcoma.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with osteosarcoma, particularly those who have not responded well to existing treatments.
Not a fit: Patients with osteosarcoma who are in advanced stages and have exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for osteosarcoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using immunotherapy for various cancers, indicating potential success for similar approaches in osteosarcoma.
Where this research is happening
Auburn, UNITED STATES
- Auburn University at Auburn — Auburn, United States (Active)
Researchers
- Principal investigator: Agarwal, Payal — Auburn University at Auburn
- Study coordinator: Agarwal, Payal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.